secwatch.observer — SEC 8-K summary
======================================

Issuer:     Moleculin Biotech, Inc. (MBRX)
CIK:        0001659617
Form:       8-K
Filed at:   2026-06-05T12:30:10+00:00
Accession:  0001437749-26-019660
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Moleculin announces strong physician intent to prescribe Annamycin in R/R AML; likelihood-to-prescribe score 6/7
--------------------------------------------------------------------------------

- Oncologists reported average likelihood-to-prescribe Annamycin of 6 out of 7, citing deep remissions and reduced cardiotoxicity.
- Physicians highlighted Annamycin's biomarker-agnostic applicability and potential to bridge patients to bone marrow transplant.
- Payers viewed Annamycin as a potentially valuable addition for R/R AML, driven by efficacy and safety profile.
- Key differentiators include MRD-negative responses and reduced cardiotoxicity, especially important for pediatric and repeat dosing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1659617/000143774926019660/0001437749-26-019660-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1659617/000143774926019660/mbrx20260604_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-26-019660

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer